http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2900322-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdf849c32d7e0f41780c1a6b776dc1e3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-08 |
| filingDate | 1979-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e25401d0be48b82d9af12182f5ced0a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88b7d7f769e1c14cb8d9c4363204f383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebe6cc6e6dfe2b8a1fa829a0133757a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a182e7ba0ef96c846ac727c971673179 |
| publicationDate | 1980-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-2900322-A1 |
| titleOfInvention | DERIVATIVES OF 3-CARBOXYRIFAMYCIN SV AND 3-CARBOXYRIFAMYCIN S, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING SUCH AS AN INTERMEDIATE PRODUCT FOR PRODUCING THE FIRST |
| abstract | 3-Carboxy-rifamycin SV and S of formulae (I) and (II) and their salts with acids and bases are new. In the formulae R is cyano, OR1, -NR2R3 or -NR4-NR5R6, R1 is a 1-4C aliphatic group which may have hydroxy, halo or lower dialkylamino substitutents, R2 and R3 are each H, 1-4C aliphatic group or an aromatic group (opt. substituted) or R2 and R3 together with the N atom form a 6-membered heterocyclic ring which may contain further O and N hetero-atoms and is opt. substd. or R5 is H or a 1-4C aliphatic group and R5 and R6 are each 1-4C aliphtic group or R4 and R5 together with the two N atoms form a 6-membered heterocyclic group which may contain further O and N hetero-atoms and is opt. substd. or R5 and R6 together with the N atom form a 6-membered heterocyclic which may contain further N and O hetero-atoms and is opt. substd. (I) are antibacterials which are administered orally, parenterally or topically to treat infections such as furunculosis, aptitis, cholecystitis etc. Minimum inhibitory concentration tests are described for Staph. aureus 209P, Klebsiella ottaviani, Salmonella p- typhi B and coli ML/35. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111018887-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111018887-B |
| priorityDate | 1979-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.